Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$78 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
35.6
Industry P/E
--
EV/EBITDA
-9.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
28,985,000
CFO
$-133.94 Mln
EBITDA
$-170.35 Mln
Net Profit
$-162.36 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aerovate Therapeutics Inc (AVTE)
| -97.1 | -97.0 | -97.0 | -99.6 | -82.4 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Aerovate Therapeutics Inc (AVTE)
| -88.1 | -22.8 | 148.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aerovate Therapeutics Inc (AVTE)
|
2.7 | 77.7 | 0.0 | -49.0 | -- | -63 | -- | 35.6 |
| 0.0 | 7.9 | 8.1 | -73.1 | -703.2 | -276.4 | -- | 0.2 | |
| 0.5 | 1.6 | 1.7 | -34.6 | -3,246.1 | -215.6 | -- | 0.2 |
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
CEO & Director
Mr. Timothy P. Noyes M.B.A.
CEO & Director
Mr. Timothy P. Noyes M.B.A.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aerovate Therapeutics Inc (AVTE) is $2.68 (NASDAQ) as of 28-Apr-2025 16:28 EDT. Aerovate Therapeutics Inc (AVTE) has given a return of -82.39% in the last 3 years.
Since, TTM earnings of Aerovate Therapeutics Inc (AVTE) is negative, P/E ratio is not available.
The P/B ratio of Aerovate Therapeutics Inc (AVTE) is 35.57 times as on 28-Apr-2025, a 803 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Aerovate Therapeutics Inc (AVTE) are Rs 884.98 and Rs 2.63 as of 04-Apr-2026.
Aerovate Therapeutics Inc (AVTE) has a market capitalisation of $ 78 Mln as on 28-Apr-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Aerovate Therapeutics Inc (AVTE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-91.12
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.